ArticleOphthalmology and therapy2026
Real-World Outcomes After Switching to Faricimab in Patients with Chronic Diabetic Macular Edema at a Tertiary Eye Center in Singapore.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionTo evaluate visual and anatomical outcomes after switching to faricimab in Singaporean patients with diabetic macular edema (DME) previously treated with other anti‑vascular endothelial growth factor (VEGF) agents or therapies.
methodsThis was a retrospective single-center cohort study with chart review. The subjects were patients with DME at the Singapore National Eye Centre who had a suboptimal response to prior therapy and therefore switched to faricimab between 2022 and 2024; all received three or four consecutive intravitreal faricimab injections on the basis of the treating physician's clinical decision. We analyzed changes in best available visual acuity (BAVA; ETDRS letters) and central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to the first follow-up after the loading of faricimab. The initial loading regimen, consisting of three or four consecutive intravitreal faricimab injections, was determined by the treating clinician. We also conducted a subgroup analysis comparing outcomes between the three-injection and four-injection groups.
resultsA total of 157 eyes from 131 patients were included, comprising 101 eyes in the three-injection group and 56 eyes in the four-injection group. The median duration of prior therapy was 1.8 years (interquartile range [IQR] 3.6). Mean BAVA improved significantly from 57.8 ± 16.5 to 62.4 ± 15.0 ETDRS letters at mean final follow-up of 6.9 weeks (p < 0.001). Mean CST decreased from 431.4 ± 129.4 µm to 334.2 ± 90 µm (p < 0.001). No significant differences in BAVA change (p = 0.39) or CST change (p = 0.58) were observed between the three‑ and four‑injection groups.
conclusionSwitching to faricimab resulted in significant short-term improvements in both visual acuity and retinal thickness even among patients with chronic DME who were previously receiving long-term treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.